New Review Flunks Most States in Tobacco Prevention Funding
WASHINGTON-Only 17 states have committed substantial funds from the tobacco settlement to tobacco prevention and cessation programs, according to a new report released by the American Cancer Society, American Heart Association, Campaign for Tobacco-Free Kids, and American Lung Association.
WASHINGTONOnly 17 states have committed substantial funds from the tobacco settlement to tobacco prevention and cessation programs, according to a new report released by the American Cancer Society, American Heart Association, Campaign for Tobacco-Free Kids, and American Lung Association. Only 6 of the 17Arizona, Indiana, Maine, Massachusetts, Minnesota, and Mississippihave met or exceeded the minimum spending recommended by the CDC20% to 25%.
Articles in this issue
First Racial-Ethnic Breast and Cervical Cancer Screening Data
Mitotic Activity Index IDs High-Risk Node-Negative Breast Cancer
Programs Help Women/Physicians Decide on Adjuvant Therapy for Breast Cancer
No Recurrence in 971 Breast Cancer Patients With Negative SLNs Sentinel Lymph Node Biopsy
Disclosure Issues in Cancer Gene Testing Worry Doctors
Functional Assessment of Geriatric Cancer Patients Needed
Mobile Mammography Programs Are Struggling to Survive
Ellence Research Fund Names 11 Grant Recipients
Hyperfractionated RT Ups Pharynx Cancer Survival
Internet Creates Virtual Radiology Department
Dioxin TCDD Finally Listed as ‘Known’ Human Carcinogen
Fish Oil Concentrate Increases Doxorubicin Efficacy in Animals
RT Plus Chemo Ups Bladder Cancer Survival
Ductal Lavage Provides Early Detection of Atypical Cells
Study Clarifies When to Start HIV Therapy
Recent Videos
Related Content
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
